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Abstract Data on the association between the SLC6A4
STin2 VNTR polymorphism and migraine are conflicting.
To perform pooled and meta-analyses, we searched for
studies published until September 2009 using electronic
databases (MEDLINE, EMBASE, Science Citation Index)
and reference lists of studies. Assessment for eligibility and
extraction of data was performed by two independent
investigators. We extracted allele and genotype frequencies
for each study. We then calculated study-specific and
pooled odds ratios (OR) and 95% confidence intervals (CI)
assuming allele and genotype models. We also calculated
pooled ORs and 95% CIs based on study-specific effect
estimates for the allele model. We included five studies
investigating the association between the STin2 VNTR
polymorphism and migraine. Results from the allele model
suggested a protective effect against migraine for the
STin2.9 and STin2.10 alleles compared to the STin2.12
allele among populations of European descent, which
however was not significant. Results from the genotype
model indicated a significant *25% reduced risk for
migraine among carriers of the 10/12 genotype compared
with carriers of the 12/12 genotype among all study pop-
ulations (OR = 0.76, 95% CI 0.60–0.97) for any migraine,
which was more pronounced among populations of Euro-
pean descent (OR = 0.68, 95% CI 0.53–0.87). Results for
migraine with and without aura were of similar magnitude,
but were not statistically significant. Our results suggest a
protective effect of non-STin2.12 alleles compared to
STin2.12 alleles, respectively, 10/12 and 10/10 genotypes
compared to the 12/12 genotype against migraine among
populations of European descent. Associations in non-
European populations may differ.
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Migraine is a common headache disorder affecting 10–
20% of the population, women three to four times more
often than men [1]. Up to one-third of migraine patients
experience an aura prior to or during the migraine
headache.
Migraine is viewed as an inherited brain disorder,
characterized by neurotransmitter imbalances leading to
neuronal dysfunctions, which then present with recurrent
headache attacks and combinations of gastrointestinal and
autonomic nervous system symptoms [1]. The neurotrans-
mitter serotonin appears to play a pivotal role and altera-
tions in serotonin metabolism and in the processing of
central serotonin-mediated responses have been described
as typical for migraineurs [2]. Following axonal release,
serotonin action is rapidly terminated by presynaptic re-
uptake [3] through the serotonin transporter SLC6A4 [4].
Furthermore, SLC6A4 is predominantly expressed in the
brainstem and midbrain [5], areas implicated in migraine
pathophysiology.
A polymorphism in intron 2 of the SLC6A4 gene has
been described consisting of a 17 bp variable number of
tandem repeats (termed STin2 VNTR). This polymorphism
involves two major alleles (termed ‘STin2.10’ and
‘STin2.12’) corresponding to 10 or 12 repeat units [6]. In
addition, low-frequency alleles (termed ‘STin2.9’ and
‘STin2.7’) have been described including nine and seven
repeat units [7]. While the biological function of this
polymorphism is unclear, STin2.12 has been reported to
possess greater transcriptional activity than STin2.10 [8].
A number of studies investigated the association
between the STin2 VNTR polymorphism and migraine,
with varying results. Some reported altered allelic or
genotypic distribution among patients with any migraine
[9], migraine with aura (MA) [10–12] or migraine without
aura (MO) [10]. Others did not find an association [13].
We sought to summarize the current data on the asso-
ciation between the SLC6A4 STin2 VNTR polymorphism
and migraine including MA and MO by systematically




We followed the guidelines for systematic reviews of
genetic association studies [14]. Two investigators (M.S.,
P.M.R.) independently searched MEDLINE, EMBASE and
Science Citation Index from inception to September 2009,
combining text words and MESH terms, where appropriate,
for serotonin and serotonin transporter (‘‘serotonin plasma
membrane transport proteins’’, ‘‘serotonin transporter’’,
‘‘serotonin’’ or ‘‘SLC6A4’’) with terms for genetic varia-
tions (‘‘gene’’, ‘‘polymorphism’’ or ‘‘genetic variation’’)
and terms for headache and migraine (‘‘headache’’,
‘‘headache disorders’’, ‘‘migraine’’ or ‘‘migraine disor-
ders’’). The search terms were combined with the
‘‘explode’’ feature where applicable. We considered full
articles without language restrictions. In addition, we
manually searched the reference list of all primary articles
and review articles.
A priori, we defined the following criteria for inclusion:
1. Studies must have a cross-sectional, case–control or
cohort design and must be published as full papers.
2. Authors must investigate patients with migraine,
diagnosed according to the criteria of the International
Headache Society (IHS) [15, 16] and healthy control
subjects.
3. Authors must provide information on genotype fre-
quencies of the SLC6A4 VNTR STin2 polymorphism
or sufficient data to calculate these.
4. In studies with overlapping cases and/or controls, the
largest study with extractable data was included.
In a first step, two investigators (M.S., T.K.) by con-
sensus identified all studies not meeting any of the pre-
specified criteria by screening the title and abstracts. These
studies were excluded. In a second step, the same investi-
gators evaluated the remaining studies in their entirety.
Studies were excluded if they did not meet all criteria.
Data extraction
Two investigators (M.S., P.M.R.) independently extracted
data from the published studies and entered them in a
customized database. Disagreements were resolved by
consensus. The extracted data included authors and title of
study, year of publication, country of origin, ethnicity of
population investigated, setting (clinic vs. population),
study design, genotyping method, migraine status (any
migraine, MA, MO), age range and gender of study par-
ticipants, study size, allele and genotype frequencies, and
information on additional genetic variants as well as gene–
gene and gene–environment interactions, if investigated. If
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not given, genotype frequencies were calculated where
possible. We did not contact the authors to collect further
information.
Statistical analysis
In contrast to single nucleotide polymorphisms, which are
characterized by two alleles and three genotypes, the
SLC6A4 STin2 VNTR polymorphism is characterized by
four alleles [6, 7]. Although studies in migraine have only
reported the STin2.9, STin2.10 and STin2.12 alleles, it still
precludes employment of simple biological models at the
allele or genotype level (additive, dominant, recessive)
based on one degree of freedom (df) tests. Further, model-
free approaches at the genotype level based on ‘number of
genotypes-1’ df yield more than one odds ratio (OR) from
one model. These cannot easily be combined for meta-
analysis to obtain single pooled effect estimates, tests sta-
tistics, and measures of heterogeneity. Hence, we used two
different, but complementary approaches, to investigate the
association of the SLC6A4 STin2 VNTR polymorphism
and migraine.
In the first approach, we investigated an association at
the allele level. For each study, we combined the STin2.9
and STin2.10 alleles and compared these to the more
frequent STin2.12 alleles, as done in a previous meta-
analysis [17]. This approach investigates whether an
excess of alleles in one of the two groups alters the risk
for migraine. We used logistic regression to calculate
odds ratios (ORs) and 95% confidence intervals (CIs) for
each study for the association between alleles of the
SLC6A4 STin2 VNTR polymorphism and migraine. We
then weighted the log of the ORs by the inverse of their
variance to obtain pooled estimates. We ran random
effects models, which include assumptions about the
variability between studies. We performed the DerSimo-
nian and Laird Q test for heterogeneity and also calcu-
lated the I2 statistic for each analysis [18]. This statistic
describes the percentage of total variation across studies
that is due to heterogeneity rather than chance (25%: low,
50%: medium, 75%: high heterogeneity). We used Gal-
braith plots to visually examine the impact of individual
studies on the overall homogeneity test statistics. We
evaluated potential publication bias visually by examining
for possible skewness in funnel plots [19] and statistically
with the methods described by Begg and Mazumdar [19]
and Egger [20].
The second approach was performed at the genotype
level. Since one of the studies [12] only presented com-
bined data for the very infrequent genotypes, we also
combined these genotypes in the other studies for further
analyses (‘other genotypes’: STin2.9/STin2.10 and
STin2.9/STin2.12). We did not further combine any of the
other genotypes. We then pooled genotype data from the
studies. Finally, we used logistic regression analysis to
evaluate the association between pooled genotypes of the
SLC6A4 STin2 VNTR polymorphism and migraine. We
created indicator variables for each genotype; the most
frequent genotype STin2.12/STin2.12 served as reference
(3 df test). We calculated odds ratios (ORs) and 95%
confidence intervals (CIs) for each of the other observed
genotypes.
We also investigated Hardy–Weinberg equilibrium
(HWE) in each study and in the pooled data, considering
the frequent alleles (STin2.10 and STin2.12).
The genotype-based approach has two advantages.
Firstly, it is biologically more meaningful, since the
genotype as opposed to the allele is the biological unit
characterizing an individual. Secondly, it makes no
assumption about the underlying biological model (model-
free) allowing for non-linear effects and thus yields effect
estimates for each genotype compared to the reference.
In both approaches, we investigated any migraine, MA
or MO. We considered p values \ 0.05 as statistically
significant. All analyses were performed using SAS
version 9.1 (SAS Institute Inc, Cary, NC) and STATA
10.1 (Stata, College Station, TX, USA). Since we only
utilized previously published data, we did not obtain the
approval of an ethics committee or a written informed
consent.
All authors had access to all of the data.
Results
For ease of readability, genotypes will be referred to by the
number of tandem repeats from here on. For example,
STin2.12/STin2.12 will be abbreviated as 12/12, STin2.10/
STin2.12 as 10/12 and STin2.10/STin2.10 as 10/10.
Figure 1 summarizes the process of identifying eligible
studies. After title and abstract evaluation, we were left
with 18 studies [9–13, 21–33]. We excluded 13 more
studies [21–33] after evaluating the full paper versions of
the remaining articles and were left with 5 studies for this
analysis [9–13].
Study characteristics
Table 1 summarizes the characteristics of the five included
studies. Four studies were performed in populations of
European descent [10–13] and one in a Turkish population
[9]. Four studies, each, presented results for any migraine
[9, 10, 12, 13] and MA [10–13] and three for MO [10, 12,
13]. All studies investigated only mixed female and male
populations, had a case–control design and used standard
polymerase chain reaction genotyping methods.
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The allele and genotype frequencies for the SLC6A4
STin2 VNTR polymorphism for migraineurs and controls
in each of the included studies are summarized in Table 2.
Table 3 summarizes for each of the studies the ORs
(95% CI) for the association between the SLC6A4 STin2
VNTR polymorphism and migraine assuming allele and
genotype models as well as p values for the HWE in the
controls. Genotype distributions in two control study pop-
ulations deviated from HWE [9, 13]. Table 4 summarizes
results from the pooled and meta-analyses based on an
allele model and Table 5 a pooled analysis based on a
genotype model.
Association between the SLC6A4 STin2 VNTR
polymorphism and migraine
In the allele model, some of the effect estimates from
individual studies suggested a reduced risk for any
migraine [10, 12], MA [10–12] or MO [10] among carriers
of the STin2.9 and STin2.10 alleles compared to carriers of
the STin2.12 allele (Table 3). However, none of the results
were statistically significant. In contrast, the study on a
Turkish population suggested a significantly increased risk
for any migraine (OR = 2.09; 95% CI 1.19–3.67) [9].
Results from the genotype model suggested a reduced
risk of the 10/12 and 10/10 genotypes for any migraine [10,
12], MA [10, 12] or MO [10] compared with the 12/12
genotype. However, the results only became statistically
significant for all three migraine categories for the 10/12
genotype in one study [10] (Table 2). There was no clear
pattern of association of the ‘other genotypes’ with
migraine, likely because they are so rare, which is also
reflected by the wide confidence intervals. In contrast, the
Turkish study [9] suggested a significantly threefold
increased risk of any migraine for carriers of the 10/12 and
10/10 genotypes, which was very similar for both geno-
types. One study did not show a clear pattern of association
for any of the genotypes with MA [11], likely due to the
small sample size. Another study [13] did not show an
association of any of the genotypes with any of the migraine
categories in either the allele or the genotype model.
The effect estimates based on the allele model from the
pooled and the meta-analyses pointed toward a protective
effect against any migraine, MA or MO for the STin2.9 and
STin2.10 alleles compared to the STin2.12 allele among
populations of European descent (Table 4). ORs from both
analyses were very similar; however, none of the results
was statistically significant. Heterogeneity among all
studies investigating any migraine was medium
(I2 = 70.4%). This was attributable to the Turkish study
[9]; analyses of studies only among populations of Euro-
pean descent did not indicate any heterogeneity. Begg’s
test and Egger’s test did not indicate publication bias
among studies in populations of European descent, while
Egger’s test suggested that there might be some publication
bias among studies investigating MO (p = 0.01).
Our pooled analyses based on a genotype model suggest












•Animal/cell culture studies: 67
•Other irrelevant topics/ gene variants: 113
18 records left after title and abstract evaluation
Full article evaluation
Exclusion because:
• did not investigate SLC6A4 STin2 VNTR 
polymorphism: 10 (Kotani, 2002; Juhasz, Neurosci Lett,
2003; Juhasz, J Neurogenetics, 2003; Marziniak, 2005; 
Kim, 2005; Borroni, 2005; Todt, 2006; Gonda, 2007; 
Wieser, 2009; Corominas, 2009)
• family study design: 2 (Monari, 1997; Karwautz, 2007)
•genotype frequencies for SLC6A4 STin2 VNTR
polymorphism cannot unambiguously be derived: 1 
(Park, 2006) 
5 articles finally included
Total number of records identified: 443
No additional records identified by
manually searching the references
Fig. 1 Process of identifying
studies
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10/12 genotype compared with carriers of the 12/12
genotype (Table 5). The pooled ORs (95% CI) among all
study populations were 0.76 (0.60–0.97) for any migraine.
When we confined our analysis to populations of European
descent, this effect appeared more pronounced
(OR = 0.68, 95% CI 0.53–0.87). The results for MA
Table 1 Characteristics of included studies investigating the association between the SLC6A4 STin2 VNTR polymorphism and migraine
Author and year Country Setting Population Study size with genotypic information Comment
Controls Any migraine MA MO
Ogilvie [10] Denmark Population Mixed 133 285 94 173
Lea [13] Australia Population Mixed 141 148 81 67 Other polymorphisms investigated: in
dopamine beta-hydroxylase gene
(DBH) and dopamine receptor 2
gene (DRD2).
Yilmaz [9] Turkey NS Mixed 79 37 – – Other polymorphisms investigated:
SLC6A4 5-HTTLPR.
Racchi [11] Italy Clinic Mixed 32 – 44 – Other polymorphisms investigated:
HTR1B 261 T [ G, HTR1B 861
G [ C, HTR2C 68 G [ C.
MA patients were compared to
unaffected family members and
unrelated controls. For the present
analysis, only data from MA patients
and unaffected controls are
considered.
Szilagyi [12] Hungary Clinic Mixed 464 87 38 49 Other polymorphisms investigated:
SCL6A4 5-HTTLPR.
Cases were children and adolescents;
controls were high school and
university students.
Total number of subjects 849 557 257 289
MA migraine with aura, MO migraine without aura, NS not specified
Table 2 Allele and genotype frequencies for the SLC6A4 STin2 VNTR polymorphism
Author Disease status Study size Allele frequencies, n (%) Genotype frequencies, n (%)






Ogilvie [10] Controls 133 3 (1.1) 107 (40.2) 156 (58.7) 3 (2.3) 19 (14.3) 68 (51.1) 43 (32.3)
Any migraine 285 14 (2.5) 187 (32.8) 369 (64.7) 14 (4.9) 38 (13.3) 105 (36.8) 128 (44.9)
MA 94 6 (3.2) 66 (35.1) 116 (61.7) 6 (6.4) 15 (16.0) 32 (34.0) 41 (43.6)
MO 173 6 (1.7) 113 (32.7) 227 (65.6) 6 (3.5) 22 (12.7) 68 (39.3) 77 (44.5)
Lea [13] Controls 141 4 (1.4) 112 (39.7) 166 (58.9) 4 (2.8) 33 (23.4) 45 (31.9) 59 (41.8)
Any migraine 148 5 (1.7) 116 (39.2) 175 (59.1) 5 (3.4) 34 (23.0) 46 (31.1) 63 (42.6)
MA 81 3 (1.9) 64 (39.5) 95 (58.6) 3 (3.7) 19 (23.5) 25 (30.9) 34 (42.0)
MO 67 2 (1.5) 52 (38.8) 80 (59.7) 2 (3.0) 15 (22.4) 21 (31.3) 29 (43.3)
Yilmaz [9] Controls 79 0 (0.0) 53 (33.5) 105 (66.5) 0 (0.0) 14 (17.7) 25 (31.6) 40 (50.6)
Any migraine 37 0 (0.0) 38 (51.4) 36 (48.6) 0 (0.0) 10 (27.0) 18 (48.6) 9 (24.3)
Racchi [11] Controls 32 2 (3.1) 30 (46.9) 32 (50.0) 2 (6.3) 9 (28.1) 12 (37.5) 9 (28.1)
MA 44 0 (0.0) 35 (39.8) 53 (60.2) 0 (0.0) 3 (6.8) 29 (65.9) 12 (27.3)
Szilagyi [12] Controls 464 13 (1.4) 340 (36.6) 575 (62.0) 13 (2.8) 59 (12.7) 220 (47.4) 172 (37.1)
Any migraine 87 3 (1.7) 55 (31.6) 116 (66.7) 3 (3.4) 8 (9.2) 38 (43.7) 38 (43.7)
MA 38 2 (2.6) 19 (25.0) 55 (72.4) 2 (5.3) 3 (7.9) 13 (34.2) 20 (52.6)
MO 49 1 (1.0) 36 (36.7) 61 (62.2) 1 (2.0) 5 (10.2) 25 (51.0) 18 (36.7)
MA migraine with aura, MO migraine without aura
a STin2.9/STin2.10 and STin2.9/STin2.12
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(OR = 0.76; 95% CI 0.55–1.04) and MO (OR = 0.76;
95% CI 0.56–1.02) were of similar magnitude, but did not
reach statistical significance. While the ORs for the 10/10
genotype also pointed toward a protective effect, they were
larger and not statistically significant. In contrast, the ‘other
genotypes’ appeared to increase the risk for any migraine
and MA, but not MO.
Sensitivity analyses
We performed two kinds of sensitivity analyses.
Firstly, we created Galbraith plots based on the ORs
from the allele models (Table 3). The plot for studies
investigating any migraine identified the Turkish study [9]
as an important source of heterogeneity, since the OR fell
outside the margin set by the z score ± 2 standard devia-
tions. An analysis excluding that study was identical to our
analysis among populations of European descent. The plots
for MA and MO did not identify any of the studies as
significant sources of heterogeneity.
Secondly, we re-ran all pooled and meta-analyses by
excluding studies where the genotype distribution deviated
from HWE in the control group [9, 13]. The effect
estimates for the allele model from the pooled and the
meta-analyses were all slightly lower. Results from the
pooled analyses remained insignificant; the ORs (95% CI)
for any migraine were 0.84 (0.70–1.02), for MA 0.88
(0.69–1.13), and for MO 0.86 (0.68–1.07). Results from
the meta-analysis were significant for any migraine
(OR = 0.79, 95% CI 0.63–0.99) and marginally significant
for MA (OR = 0.76, 95% CI 0.57–1.00; p = 0.05). The
OR (95% CI) for MO was 0.83 (0.63–1.09). The results
from the genotype model remained very similar. For
example, the OR (95% CI) for the 10/12 genotype was 0.64
(0.48–0.86) for any migraine, 0.76 (0.53–1.09) for MA and
0.73 (0.52–1.02) for MO compared to the 12/12 genotype.
Discussion
The main results from these pooled and meta-analyses on
the association between the SLC6A4 STin2 VNTR poly-
morphism and migraine are that non-STin2.12 alleles
compared to STin2.12 alleles and 10/12 and 10/10 geno-
types compared to the 12/12 genotype appear to protect
against migraine among populations of European descent.
Table 4 Allele model: pooled and meta-analyses of the association between the SLC6A4 STin2 VNTR polymorphism and migraine
Migraine
category












Any migraine All [9, 10, 12, 13] 4 0.95 (0.81–1.11) 1.00 (0.72–1.41) 10.1 3 0.02 70.4 0.17 0.045
European descent [10, 12, 13] 3 0.89 (0.76–1.05) 0.85 (0.70–1.02) 1.3 2 0.54 0 0.60 0.63
MA European descent [10–13]b 4 0.93 (0.76–1.14) 0.83 (0.66–1.05) 2.7 3 0.44 0 0.50 0.17
MO European descent [10, 12, 13]b 3 0.88 (0.72–1.08) 0.86 (0.69–1.08) 1.5 2 0.48 0 0.12 0.01
MA migraine with aura, MO migraine without aura
a STin2.9 and STin2.10 alleles were grouped together and compared to STin2.12 as the reference
b There are no studies available for MA and MO among populations of non-European descent
Table 5 Genotype model: pooled analysis of the association between the SLC6A4 STin2 VNTR polymorphism and migraine
Migraine
category
Study populations No of
studies
HWE 10/12 10/10 Othera
Odds ratiob
(95% CI)
p value Odds ratiob
(95% CI)
p value Odds ratiob
(95% CI)
p value
Any migraine All [9, 10, 12, 13] 4 0.18 0.76 (0.60–0.97) 0.03 0.95 (0.69–1.31) 0.75 1.45 (0.77–2.72) 0.25
European descent [10, 12, 13] 3 0.58 0.68 (0.53–0.87) 0.002 0.86 (0.62–1.21) 0.39 1.32 (0.70–2.47) 0.39
MA European descent [10–13]c 4 0.40 0.76 (0.55–1.04) 0.09 0.88 (0.58–1.34) 0.56 1.32 (0.62–2.82) 0.47
MO European descent [10, 12, 13]c 3 0.58 0.76 (0.56–1.02) 0.07 0.84 (0.55–1.26) 0.40 0.99 (0.44–2.25) 0.99
HWE p value for Hardy–Weinberg equilibrium, MA migraine with aura, MO migraine without aura
a STin2.9/STin2.10 and STin2.9/STin2.12
b Genotype 12/12 was used as the reference
c There are no studies available for MA and MO among populations of non-European descent
J Headache Pain (2010) 11:317–326 323
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Results from the allele analyses were not statistically sig-
nificant. Results from genotype analyses suggested the
smallest effect estimates for the 10/12 genotype translating
into a *25% reduced risk and became statistically sig-
nificant for the largest group of patients with any migraine.
The effect estimates were similar for any migraine, MA
and MO. In contrast, associations may differ in non-
European populations, as suggested by a Turkish study [9]
showing a threefold increased risk for any migraine among
carriers of the 10/12 and 10/10 genotypes.
Migraine has a clear genetic component with a herita-
bility as high as 50% [34]. However, identifying genetic
markers for common forms of migraine has been difficult
[35].
Serotonin plays a pivotal role in migraine [2] and a
dysfunctional serotonergic system agrees with patho-
physiological models of a cortical dysbalance [36] and
treatment success of triptans [37]. Among the main fea-
tures in migraineurs are changes in serotonin metabolism
and in the processing of central serotonin-mediated
responses [2]. Synaptic serotonin is moved to the intra-
cellular space by the serotonin transporter SLC6A4 and
two polymorphisms in the SLC6A4 gene have been
investigated with regard to their association with
migraine: the 5-HTTLPR and the STin2 VNTR poly-
morphisms. In a recent meta-analysis on the association
of the 5-HTTLPR polymorphism and migraine, we did
not find an overall association among Europeans and
Asians; however, gender and migraine aura status may
have modifying roles among Europeans [38]. Similar to
studies on the 5-HTTLPR polymorphism, studies on the
association between the STin2 VNTR polymorphism and
migraine came to conflicting results. Some have reported
an altered allelic or genotypic distribution among patients
with any migraine [9], MA [10–12] or MO [10], while
others did not find an association [13]. This may in part
be due to differences in sample size and study charac-
teristics. In addition, it is unclear whether only a specific
combination of alleles, i.e., a single genotype, or the
simple presence of one allele, i.e., multiple genotypes,
might alter the risk for migraine.
Results from our analyses indicating a protective role
against migraine for non-STin2.12 alleles, respectively, for
10/12 and 10/10 genotypes of the STin2 VNTR polymor-
phism in populations of European descent became only
statistically significant for the association between the
10/12 genotype and any migraine. However, we are confident
that this reflects a true association and is not a false positive
signal for two reasons. Firstly, results from the allele and
genotype models agree by pointing toward the same
direction of a protective effect of non-STin2.12 alleles/non-
12/12 genotypes. Second, our sensitivity analyses suggest
similar or even smaller effect estimates and p values.
Employing a genotype model in addition to an allele
model yields further valuable information. Firstly, it indi-
cated that both the 10/12 and 10/10 genotypes reduced the
risk for migraine compared to the 12/12 genotype. This
allows for two possible interpretations. On the one hand,
the STin2.10 allele may exert a dominant effect over the
STin2.12 allele. The higher ORs and non-significant p
values for the 10/10 genotype may be due to the smaller
number of 10/10 than 10/12 genotypes (Table 2). Alter-
natively, the protective effect may only occur with the 10/
12 genotype, as suggested by the statistical significance of
the results. It may be speculated that an unequal number of
tandem repeats on the two chromosomes (heterozygotes)
impairs transporter function, which does not occur for
homozygotes. Examples from other gene variants exist, for
example the GNB3 825C[T polymorphism [39], where the
largest association is seen among carriers of heterozygous
genotypes. Secondly, providing estimates for genotypes, as
opposed to alleles, is biologically more meaningful, since
the genotype is the genetic unit characterizing each indi-
vidual. Thirdly, the *25% reduced risk for migraine of the
10/12 genotype appears moderate; however, it is in keeping
with migraine being a complex disorder. This means that
multiple genetic (and environmental) factors with small to
moderate effects determine the susceptibility for migraine.
Results for the ‘other genotypes’ (9/10 and 9/12) sug-
gested that the risk for migraine may be increased for any
migraine and MA (Table 5). However, caution is warranted
since the frequencies of the ‘other genotypes’ are very rare
rendering the results susceptible to minor alterations in
genotype distribution.
The functional implications of the STin2 VNTR poly-
morphism are not well understood. Expression studies have
shown that the STin2.10 and STin2.12 alleles enhance
transcriptional activity, Stin2.10 significantly less than
STin2.12 [8]. We may speculate that STin2.10 leads to a
lower number of SLC6A4 transporters, hence less serotonin
reuptake and more synaptic (maybe ‘normal’) serotonin
activity compared to the STin2.12 allele. This may reduce
the risk for migraine as also suggested by our analyses.
However, functional investigations of the platelet serotonin
transporter do not agree, since they show that serotonin
uptake is unaltered by the STin2 VNTR polymorphism [40].
The following aspects of our meta-analysis need to be
considered. First, migraine is a heterogeneous disorder with
a wide clinical spectrum [35]. Patients with different clin-
ical phenotypes have been diagnosed as having migraine,
and even strict classification according to IHS criteria [15,
16] may not sufficiently capture this variability and may be
a source of misclassification in all studies. Second, the total
number of studies identified was five, which limits the
statistical power. Hence, a larger sample size than available
from all the studies combined might be necessary to
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improve precision of our results. While the systematic
review part allows for an overview of the available studies
including individual results, the meta-analytic part also
facilitates evaluation of magnitude and direction of pooled
effect estimates including sources of heterogeneity. Third,
SLC6A4 is a large polymorphic gene comprising 37,810 bp
organized into 15 exons and 14 introns with 380 single
nucleotide polymorphisms (SNPs) reported [41, 42]. Some
of these SNPs may be associated with migraine [43].
Hence, in addition to the SLC6A4 STin2 VNTR and 5-
HTTLPR polymorphisms, these SNPs may also affect
transporter production and function. Fourth, serotonin’s
role in migraine is not just determined by transporter
activity, but also by its functional effect at the receptor
level. Serotonin receptor genes are likewise polymorphic
and some of these variants may be associated with migraine
[22]. Fifth, in addition to serotonin, other neurotransmitters
such as dopamine, orexin and glutamate are important in
migraine pathophysiology [44]. Hence, migraine suscepti-
bility is a function of the interaction between various
neurotransmitters, which again is determined by the inter-
action of various genetic variants. Sixth, migraine suscep-
tibility is different between women and men, as indicated
by the higher prevalence among women [45]. However, we
had no means to investigate a gender differential genetic
effect of the STin2 VNTR polymorphism, since all studies
were performed in mixed female and male populations and
gender-stratified genotypic information was unavailable.
Seventh, associations with migraine may differ by ethnic-
ity, especially since the genotype distribution of the STin2
VNTR polymorphism shows ethnic differences [46, 47].
The available studies provide limited indication for that.
While the 10/12 and 10/10 genotypes appeared to protect
against migraine in populations of European descent, one
Turkish study [9] reported an increased risk. Eighth,
genotypes deviated from HWE in two studies [9, 13].
However, sensitivity analyses after excluding these studies
did not alter our results. Finally, we only used extractable
data from the papers. One paper did not unequivocally
indicate genotype frequencies for each of the STin2 VNTR
genotypes [31]. The study was excluded. However, the
authors only investigated MO; hence, this study would not
have altered our results for any migraine and MA. In
addition, the authors reported a higher frequency of the
12/12 genotype in patients with MO, which corresponds
with our results. Thus, including this study would likely not
have changed our results for MO either.
Conclusion
The 10/12 genotype of the SLC6A4 STin2 VNTR poly-
morphism translates into a *25% reduced risk for any
migraine. However, additional studies with large sample
sizes of migraineurs and controls seem warranted. Studies
should not just be carried out in populations of European
descent, but also in non-European populations. In addition
to overall results, results should also be presented stratified
by gender and migraine aura status. Finally, analyses should
focus on main gene effects and gene–gene interactions
investigated only if the sample size is reasonably large.
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